Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial
Background: Mizoribine (MZR) is an immunosuppressive drug used in Japan for treating patients with lupus nephritis and nephrotic syndrome and has been also reportedly effective in patients with immunoglobulin A (IgA) nephropathy. However, to date, few randomized control studies of MZR are performed...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
The Korean Society of Nephrology
2017-06-01
|
| 丛编: | Kidney Research and Clinical Practice |
| 主题: | |
| 在线阅读: | https://doi.org/10.23876/j.krcp.2017.36.2.159 |